

## **SARS-CoV-2 Spike Protein S1-Receptor-Binding Domain-Kappa (B.1.617.1)\_HEK**

### **Description:**


InVivo offers a recombinant form of the Spike protein receptor binding domain (RBD) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on Wuhan-Hu-1-isolate (MN908947), which is produced under serum-free conditions in HEK-INV cells (InVivo proprietary optimized; human embryonic kidney, HEK293 cells).

### **RBD-Kappa (B.1.617.1) variant; containing mutations L452R, E484Q.**

Protein design and manufacturing process is based on InVivo's RBD protein (aa 319-541). The protein includes a C-terminal hexa-histidine-tag and is purified using immobilized metal exchange chromatography (IMAC) and preparative SEC (for polishing).

<b>Product-ID:</b>	S1-RBD-Kappa (B.1.617.1)_HEK
<b>Expression System:</b>	Mammalian; HEK
<b>Protein Accession Number:</b>	GenBank: <a href="#">QHD43416.1</a> / UniProt: <a href="#">P0DTC2</a>
<b>Amino Acids:</b>	Arg319–Phe541, modified as mentioned above
<b>Mutations:</b>	L452R, E484Q
<b>Mature Protein N-Term:</b>	Arg319 (predicted)
<b>Tag:</b>	6 x His-Tag; C-terminal
<b>Expected Molecular Weight:</b>	26 kDa ( <i>glycosylated form runs at 25-40 kDa in gel electrophoresis</i> )
<b>Formulation:</b>	Liquid, 20 mM NaPP, 300 mM NaCl pH 7.2
<b>Concentration:</b>	≥ 0.5 mg/ mL
<b>Purity:</b>	≥ 90% ( <i>via analytical CGE under reducing conditions</i> )

**The product is for research use or for further manufacturing only.**



**SARS-CoV-2 receptor-binding domains (RBD-Wuhan, Kappa, Delta, Alpha, Gamma, Alpha +E484K and Beta) recombinantly expressed in HEK cells tested as solid phase bound capture antigens at 2 µg/mL in an in-house SARS-CoV-2 IgG ELISA.**

14 SARS-CoV-2 positive patient serum samples (obtained before October 2020) were applied. The line indicates the median of the absorbance values.